Compare LPL & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LPL | AMRX |
|---|---|---|
| Founded | 1985 | 2002 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 3.7B |
| IPO Year | 2004 | 2018 |
| Metric | LPL | AMRX |
|---|---|---|
| Price | $4.45 | $13.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | N/A | ★ $15.60 |
| AVG Volume (30 Days) | ★ 2.0M | 1.4M |
| Earning Date | 05-14-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 157.89 |
| EPS | N/A | ★ 0.22 |
| Revenue | N/A | N/A |
| Revenue This Year | $1.35 | $4.48 |
| Revenue Next Year | $2.94 | $7.13 |
| P/E Ratio | ★ $25.64 | $59.44 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.97 | $7.02 |
| 52 Week High | $5.67 | $15.42 |
| Indicator | LPL | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.04 | 60.20 |
| Support Level | $4.16 | $12.45 |
| Resistance Level | $5.07 | $13.54 |
| Average True Range (ATR) | 0.16 | 0.51 |
| MACD | -0.04 | 0.05 |
| Stochastic Oscillator | 27.16 | 69.21 |
LG Display Co Ltd is a South Korea-based company that is principally engaged in developing, manufacturing, and selling TFT-LCD and OLED display panels. The company's products consist of panels for notebook computers, monitors, televisions, smartphones, tablets, and others. The company conducts direct sales through overseas subsidiaries in several countries, including the United States, Germany, Japan, Taiwan, China, and Singapore. These subsidiaries conduct sales activities and offer technical support to clients. The company generates the majority of its revenue from overseas markets, with the rest from South Korea.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.